<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8065">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01686204</url>
  </required_header>
  <id_info>
    <org_study_id>H12-168</org_study_id>
    <nct_id>NCT01686204</nct_id>
  </id_info>
  <brief_title>Reduction of Obesity-Associated Intestinal Inflammation by Low-Fat Dairy Yogurt</brief_title>
  <official_title>Reduction of Obesity-Associated Intestinal Inflammation by Low-Fat Dairy Yogurt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dairy Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Connecticut</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this work is to conduct a clinical trial in obese and non-obese
      individuals testing the ability of low-fat dairy yogurt to improve gastrointestinal health
      and reduce chronic inflammation. Our central hypothesis is that short and long-term
      consumption of low-fat dairy yogurt will reduce inflammation to a greater extent in obese
      individuals by improving intestinal barrier function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Plasma sCD14</measure>
    <time_frame>Change from baseline at 3, 6, and 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following a high fat, high calorie meal at baseline and 9 wk</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma IL-6</measure>
    <time_frame>Baseline, 3, 6, 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following a high fat, high calorie  meal at baseline and 9 wk</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Monocyte gene expression</measure>
    <time_frame>Baseline, 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Plasma lipopolysaccharide binding protein</measure>
    <time_frame>Baseline, 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Plasma endotoxin</measure>
    <time_frame>Baseline, 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Plasma core antibodies to endotoxin</measure>
    <time_frame>Baseline, 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Plasma endocannabinoids</measure>
    <time_frame>Baseline, 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Plasma IL-10</measure>
    <time_frame>Baseline, 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Plasma C-reactive protein</measure>
    <time_frame>Baseline, 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Tumor Necrosis Factor-alpha</measure>
    <time_frame>Baseline, 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Plasma tumor necrosis factor receptor</measure>
    <time_frame>Baseline, 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Intestinal Barrier Function</condition>
  <condition>Chronic Inflammation</condition>
  <arm_group>
    <arm_group_label>Non-obese individuals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily consumption of 12 oz lowfat yogurt or soy pudding for 9 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese individuals</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption of 12 oz of soy pudding or low fat dairy yogurt daily for 9 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low fat dairy yogurt</intervention_name>
    <description>Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks</description>
    <arm_group_label>Non-obese individuals</arm_group_label>
    <arm_group_label>Obese individuals</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Soy pudding</intervention_name>
    <description>Consumption of 12 oz of low fat soy pudding daily for 9 weeks.</description>
    <arm_group_label>Non-obese individuals</arm_group_label>
    <arm_group_label>Obese individuals</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premenopausal women

          -  BMI from 18.5-27 and 30-40 kg/m2

          -  resting blood pressure &lt;140/90 mmHg

          -  not taking medication to control hypertension

          -  stable body weight for the previous 2 months

          -  willing to maintain a normal exercise level and avoid exercise 24 h prior to blood
             sampling

          -  willing to avoid yogurt and probiotic-containing foods or consume 2 servings of
             yogurt for the duration of the study

        Exclusion Criteria:

          -  previous diagnoses of CVD, diabetes, or arthritis (except for osteo-arthritis)

          -  currently being treated for cancer (i.e., chemotherapy, radiation therapy)

          -  prescribed estrogen replacement therapy

          -  practicing weight-loss, vegetarian, kosher,  or vegan diets

          -  currently taking dietary supplements

          -  exceed alcohol consumption more than moderate drinking (1 drink/day or a total of
             7/week)

          -  actively using antibiotics

          -  taking anti-inflammatory drugs

          -  have allergies to soy, egg or milk

          -  perimenopausal or menopausal symptoms
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley W Bolling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Dimarco</last_name>
    <phone>860-420-9841</phone>
    <email>uconn.yogurt@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nutritional Sciences</name>
      <address>
        <city>Storrs</city>
        <state>Connecticut</state>
        <zip>06269</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley W Bolling, PhD</last_name>
      <phone>860-486-2180</phone>
      <email>bradley.bolling@uconn.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley W Bolling, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cag.uconn.edu/nutsci/nutsci/studies.html</url>
    <description>University of Connecticut Department of Nutritional Sciences Ongoing Research Studies</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>September 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Connecticut</investigator_affiliation>
    <investigator_full_name>Bradley Bolling</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Yogurt</keyword>
  <keyword>Intestine</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Obese</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
